This site is intended for US-based Health Care Professionals only.
For your patients who prefer to self-inject, ORENCIA offers 2 subcutaneous administration options via self-injection devices.1
ORENCIA prefilled syringe allows patients once-weekly self-injection at home1
Recommendations for Subcutaneous Administration1
- ORENCIA prefilled syringes are intended for:
- Subcutaneous use only and are not intended for intravenous infusion
- Use under the guidance of a physician or healthcare practitioner
- After proper training in subcutaneous injection technique, a patient or the patient’s caregiver may administer a subcutaneous injection of ORENCIA if a physician/
healthcare practitioner determines that it is appropriate - Instruct patients and/or caregivers to follow the directions provided in the Instructions for Use for additional details on administration. Specifically instruct patients to inject the full amount (which provides the proper dose of ORENCIA), rotate injection sites, and to avoid injections into areas where the skin is tender, bruised, red, or hard
- Visually inspect for particulate matter and discoloration prior to administration. Do not use ORENCIA prefilled syringes exhibiting particulate matter or discoloration. ORENCIA should be clear to slightly opalescent and colorless to pale yellow
ORENCIA SC may be initiated with or without an IV loading dose1
- For patients initiating therapy with an IV loading dose, administer ORENCIA as a single IV infusion (as per body weight categories below), followed by the first ORENCIA SC injection administered within
1 day of the IV infusion - Patients switching from ORENCIA IV to ORENCIA SC administration should take their first SC dose instead of their next scheduled IV dose
Adult weight-based dosing
Each vial provides 250 mg of abatacept for administration.
125-mg SC injection is supplied in a prefilled syringe with BD UltraSafe Passive™ needle guard for once-weekly use.
Device highlights1*
*125-mg syringe shown
(29-gauge needle)
National Drug Code (NDC):
0003-2188-11 (125 mg/mL): pack of 4 syringes with a passive needle safety guard
Selected Important
Safety Information
Increased Risk of Infection with Concomitant Use with TNF Antagonists, Other Biologic RA/PsA Therapy, or JAK Inhibitors: Concurrent therapy with ORENCIA and a TNF antagonist is not recommended. In controlled clinical trials, adult RA patients receiving concomitant intravenous ORENCIA and TNF antagonist therapy experienced more infections (63% vs 43%) and serious infections (4.4% vs 0.8%) compared to patients treated with only TNF antagonists, without an important enhancement of efficacy. Additionally, concomitant use of ORENCIA
with other biologic RA/PsA therapy or JAK
inhibitors is not recommended.
ORENCIA ClickJect™ Autoinjector—automatically delivers the full dose with one push of a button1
Recommendations for subcutaneous administration1
- ORENCIA ClickJect autoinjectors are intended for:
- Subcutaneous use only and are not intended for intravenous infusion
- Use under the guidance of a physician or healthcare practitioner
-
After proper training in subcutaneous injection technique, a patient or the patient’s caregiver may administer a subcutaneous injection of ORENCIA if a physician/
healthcare practitioner determines that it is appropriate. - Instruct patients and/or caregivers to follow the directions provided in the Instructions for Use for additional details on administration. Specifically instruct patients to inject the full amount (which provides the proper dose of ORENCIA), rotate injection sites, and to avoid injections into areas where the skin is tender, bruised, red, or hard
- Visually inspect for particulate matter and discoloration prior to administration. Do not use ORENCIA prefilled syringes exhibiting particulate matter or discoloration. ORENCIA should be clear to slightly opalescent and colorless to pale yellow
ORENCIA SC may be initiated with or without an IV loading dose1
-
For patients initiating therapy with an IV loading dose, administer ORENCIA as a single IV infusion (as per body weight categories below), followed by the first ORENCIA SC injection administered within
1 day of the IV infusion - Patients switching from ORENCIA IV to ORENCIA SC administration should take their first SC dose instead of their next scheduled IV dose
Each vial provides 250 mg of abatacept for administration.
125-mg SC injection is supplied in the ClickJect™ Autoinjector for once-weekly use.
Device highlights
Accurate dose self-injection comes with push-button operation and confirmation that the full dose has been injected.2
National Drug Code (NDC): 0003-2188-51 (pack of 4 injectors)1
Selected Important
Safety Information
Hypersensitivity: There were 2 cases (<0.1%; n=2688) of anaphylaxis reactions in clinical trials with adult RA patients treated with intravenous ORENCIA. Other reactions potentially associated with drug hypersensitivity, such as hypotension, urticaria, and dyspnea, each occurred in <0.9% of patients. There was one case of a hypersensitivity reaction with ORENCIA in pJIA clinical trials
Storage and handling for ORENCIA SC prefilled syringe and ORENCIA ClickJectTM Autoinjector
- Refrigerate ORENCIA solution supplied in a prefilled syringe or ClickJect™ Autoinjector at 36°F to 46°F (2°C to 8°C)
- Do not use beyond the expiration date on the prefilled syringe
or autoinjector* - Protect from light by storing in the original package until time of use
- Do not allow the prefilled syringe or autoinjector to freeze
*If you find any product defects or the syringe is past its expiration date, call
References: 1. ORENCIA [package insert]. Princeton, NJ: Bristol-Myers Squibb Company. 2. Schiff M, Koo J, Jin E, et al. Usability and acceptability of the abatacept pre-filled autoinjector for the subcutaneous treatment of rheumatoid arthritis. Adv Ther. 2016;33(2):199-213. doi:10.1007/S12325-016-0286-9